Literature DB >> 19332667

Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli.

Jennifer M Adams-Haduch, Brian A Potoski, Hanna E Sidjabat, David L Paterson, Yohei Doi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19332667      PMCID： PMC2687206          DOI： 10.1128/AAC.00290-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England.

Authors:  David M Livermore; Russell Hope; Elizabeth J Fagan; Marina Warner; Neil Woodford; Nicola Potz
Journal:  J Antimicrob Chemother       Date:  2006-03-10       Impact factor: 5.790

Review 2.  Carbapenemases: the versatile beta-lactamases.

Authors:  Anne Marie Queenan; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

3.  Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.

Authors:  Daniel Curcio
Journal:  J Clin Microbiol       Date:  2008-05       Impact factor: 5.948

4.  In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.

Authors:  R Naesens; J P Ursi; J Van Schaeren; A Jeurissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-19       Impact factor: 3.267

5.  In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.

Authors:  Hector Rodriguez-Villalobos; Vincent Malaviolle; Joëlle Frankard; Ricardo de Mendonça; Claire Nonhoff; Marc J Struelens
Journal:  J Antimicrob Chemother       Date:  2006-02-24       Impact factor: 5.790

6.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

7.  In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units.

Authors:  Y Glupczynski; T-D Huang; C Berhin; G Claeys; M Delmée; L Ide; G Ieven; D Pierard; H Rodriguez-Villalobos; M Struelens; J Vaneldere
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11       Impact factor: 3.267

8.  Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities.

Authors:  Carl Urban; Patricia A Bradford; Margareta Tuckman; Sorana Segal-Maurer; Wehbeh Wehbeh; Louise Grenner; Rita Colon-Urban; Noriel Mariano; James J Rahal
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

9.  In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae.

Authors:  Anima Poudyal; Benjamin P Howden; Jan M Bell; Wei Gao; Roxanne J Owen; John D Turnidge; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2008-10-15       Impact factor: 5.790
  9 in total
  14 in total

1.  Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Gina K Thomson; James W Snyder; Christi L McElheny; Kenneth S Thomson; Yohei Doi
Journal:  J Clin Microbiol       Date:  2015-12-30       Impact factor: 5.948

Review 2.  Pharmacokinetics and Pharmacodynamics of Temocillin.

Authors:  Kevin Alexandre; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

3.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors:  N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-03       Impact factor: 3.267

4.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 6.  Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance.

Authors:  Johann D D Pitout; Patrice Nordmann; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 8.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

Review 9.  Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy.

Authors:  Constance Schultsz; Suzanne Geerlings
Journal:  Drugs       Date:  2012-01-01       Impact factor: 11.431

Review 10.  A new strategy to fight antimicrobial resistance: the revival of old antibiotics.

Authors:  Nadim Cassir; Jean-Marc Rolain; Philippe Brouqui
Journal:  Front Microbiol       Date:  2014-10-20       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.